Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
The Japanese government should establish a “command tower” function beyond the purview of the health ministry as a single agency that will integrally manage both measures to boost drug discovery capabilities and pharma pricing rules, a ruling party legislator tells…
To read the full story
Related Article
- LDP Project Team Submits Proposal to Prime Minister
June 5, 2023
- LDP OKs Project Team Proposal to Boost Pharma Innovation, Create Command Tower
May 31, 2023
- LDP Project Team to Finalize Pharma Policy Proposal for Honebuto by May-End, Submit It to Prime Minister
May 17, 2023
- Wholesaler Lobby Raps Politicians over Product Coverage of Off-Year Cuts
April 18, 2023
- LDP Gathers Steam towards Pharma Policy Proposal Next Month, Sees Honebuto as Make-or-Break Milestone
April 18, 2023
- LDP Project Team Calls for Price Maintenance During Patent Period and Rethink of Off-Year Cuts
April 11, 2023
REGULATORY
- LDP Tariff Task Force Broadly OKs First Proposal
April 22, 2025
- GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
April 22, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Diuretic, Hypertension Drugs, Zolgensma under PMDA Risk Review
April 21, 2025
- Chugai’s DMD Gene Therapy Now in Line for Conditional Approval
April 21, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…